Global Viral Vectors and Plasmid DNA Manufacturing Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Viral Vectors and Plasmid DNA Manufacturing Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Viral Vector and Plasmid DNA is product of gene therapy, which is used in diagnosis and treatment of diseases such as cancer, inherited diseases, viral infections, and others. The therapeutic DNA is introduced in host with the help of a vector. Adeno associated virus based vector are much safer as compared with others viral vectors due to its integration at same site in human genome, and has wide application in various disorders such as Alzheimer’s disease.

Market Overview:

The latest research study on the global Viral Vectors and Plasmid DNA Manufacturing market finds that the global Viral Vectors and Plasmid DNA Manufacturing market reached a value of USD 737.37 million in 2022. It’s expected that the market will achieve USD 1467.75 million by 2028, exhibiting a CAGR of 12.16% during the forecast period.

Region Overview:

From 2023-2028, United States is estimated to witness robust growth prospects.

Company Overview:

Brammer Bio is one of the major players operating in the Viral Vectors and Plasmid DNA Manufacturing market, holding a share of 8.43% in 2019.

Brammer Bio, LLC operates as a contract development and manufacturing firm. The Company focuses on developing and commercializing gene therapies. Brammer Bio serves customers in the United States.

Richter-Helm BioLogics GmbH & Co. KG operates as a biotech company. The Company offers recombinant proteins and peptides, plasmid DNA, and bacterial vaccines. Richter-Helm BioLogics serves customers worldwide.

Segmentation Overview:

Among different product types, Plasmid DNA segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Cancers segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Viral Vectors and Plasmid DNA Manufacturing market covered in Chapter 3:

FinVector
BioReliance
Richter-Helm
Biovian
UniQure
PlasmidFactory
Aldevron
Eurogentec
Cell and Gene Therapy Catapult
VGXI
MassBiologics
Cobra Biologics
Brammer Bio
Oxford BioMedica
Lonza
FUJIFILM Diosynth Biotechnologies
MolMed

In Chapter 4 and Chapter 14.2, on the basis of types, the Viral Vectors and Plasmid DNA Manufacturing market from 2018 to 2029 is primarily split into:

Plasmid DNA
Viral Vectors

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Viral Vectors and Plasmid DNA Manufacturing market from 2018 to 2029 covers:

Cancers
Inherited Disorders
Viral Infections

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)